Compare Stocks: ATAI, CORT, AXSM, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
AXSM Axsome Therapeutics	$141.69 -1.9%	$171.45	$123.00 ▼ $260.19	$7.45B	0.86	1.14 million shs	972,544 shs
CORT Corcept Therapeutics	$72.94 -1.0%	$103.70	$28.66 ▼ $126.38	$8.07B	0.54	1.29 million shs	1.11 million shs
LNTH Lantheus	$101.59 +0.3%	$100.32	$51.47 ▼ $111.86	$6.62B	0.01	1.12 million shs	758,036 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	0.00%	+1.24%	+69.75%
AXSM Axsome Therapeutics	0.00%	+7.04%	-12.42%	-33.69%	+0.59%
CORT Corcept Therapeutics	0.00%	+0.23%	-35.66%	-36.28%	-6.95%
LNTH Lantheus	0.00%	+0.97%	+1.60%	+0.63%	+86.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
AXSM Axsome Therapeutics	$141.69 -1.9%	$171.45	$123.00 ▼ $260.19	$7.45B	0.86	1.14 million shs	972,544 shs
CORT Corcept Therapeutics	$72.94 -1.0%	$103.70	$28.66 ▼ $126.38	$8.07B	0.54	1.29 million shs	1.11 million shs
LNTH Lantheus	$101.59 +0.3%	$100.32	$51.47 ▼ $111.86	$6.62B	0.01	1.12 million shs	758,036 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	0.00%	+1.24%	+69.75%
AXSM Axsome Therapeutics	0.00%	+7.04%	-12.42%	-33.69%	+0.59%
CORT Corcept Therapeutics	0.00%	+0.23%	-35.66%	-36.28%	-6.95%
LNTH Lantheus	0.00%	+0.97%	+1.60%	+0.63%	+86.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.07	Hold	$10.56	43.62% Upside
AXSM Axsome Therapeutics	2.86	Moderate Buy	$266.21	87.88% Upside
CORT Corcept Therapeutics	2.50	Moderate Buy	$139.50	91.25% Upside
LNTH Lantheus	2.21	Hold	$107.44	5.76% Upside

Current Analyst Ratings Breakdown

Latest ATAI, CORT, AXSM, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/13/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$249.00 ➝ $223.00
11/4/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
11/4/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$284.00 ➝ $272.00
11/4/2026	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$165.00 ➝ $173.00
11/3/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/3/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$256.00 ➝ $239.00
11/3/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$247.00 ➝ $249.00
11/3/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$295.00 ➝ $273.00
11/3/2026	AXSM Axsome Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$275.00 ➝ $250.00
11/3/2026	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$246.00 ➝ $220.00
10/27/2026	CORT Corcept Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	666.46	N/A	N/A	$0.69 per share	10.65
AXSM Axsome Therapeutics	$865.27M	8.61	N/A	N/A	$2.00 per share	70.85
CORT Corcept Therapeutics	$761.41M	10.48	$0.89 per share	81.65	$7.62 per share	9.57
LNTH Lantheus	$1.56B	4.25	$6.41 per share	15.86	$20.73 per share	4.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	N/A
AXSM Axsome Therapeutics	-$183.17M	-$3.06	N/A	38.71	N/A	-18.18%	-198.73%	-22.03%	N/A
CORT Corcept Therapeutics	$99.65M	$1.27	57.43	20.04	N/A	16.53%	22.56%	17.83%	N/A
LNTH Lantheus	$233.56M	$4.06	25.02	18.11	N/A	17.28%	29.26%	15.40%	N/A

Latest ATAI, CORT, AXSM, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LNTH Lantheus	$1.23	$1.68	+$0.45	$0.33	$355.74 million	$389.91 million
11/3/2026	Q3 2026	CORT Corcept Therapeutics	$0.84	$1.01	+$0.17	$1.01	$339.13 million	$340.47 million
11/2/2026	Q3 2026	AXSM Axsome Therapeutics	-$0.6343	-$0.25	+$0.3843	-$0.25	$249.19 million	$259.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
AXSM Axsome Therapeutics	1.21	1.42	1.34
CORT Corcept Therapeutics	N/A	3.00	2.94
LNTH Lantheus	0.42	3.25	3.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
AXSM Axsome Therapeutics	925	52.60 million	41.76 million	Optionable
CORT Corcept Therapeutics	730	109.44 million	86.79 million	Optionable
LNTH Lantheus	1,193	65.40 million	64.29 million	Optionable

ATAI, CORT, AXSM, and LNTH Headlines

Recent News About These Companies

Lantheus (NASDAQ:LNTH) Stock Sold Off by Rep. Gilbert Ray Cisneros, Jr.

November 12 at 8:00 AM | marketbeat.com

Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

November 12 at 8:00 AM | marketbeat.com

Lantheus Holdings stock in focus after third-quarter results

November 11, 2026 | ad-hoc-news.deA

Lantheus (NASDAQ:LNTH): Strongest Q3 results from the healthcare equipment and supplies group

November 10, 2026 | msn.com

PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility

November 9, 2026 | prnewswire.com

University of Texas Texas AM Investment Management Co. Acquires 17,859 Shares of Lantheus Holdings, Inc. $LNTH

November 9, 2026 | marketbeat.com

Lantheus' Q3 Adjusted Earnings, Revenue Rise

November 5, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 5, 2026 | marketscreener.comM

Lantheus Holdings Releases Q3 2026 Financial Results

November 5, 2026 | news.alphastreet.comN

Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q3 Adjusted EPS $1.68 per Share, vs. FactSet Est of $1.23

November 5, 2026 | marketscreener.comM

Lantheus Holdings: Q3 earnings snapshot

November 5, 2026 | msn.com

Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

November 5, 2026 | globenewswire.com

Lantheus Reports Third Quarter 2026 Financial Results

November 5, 2026 | globenewswire.com

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting

November 2, 2026 | finance.yahoo.com

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting

November 2, 2026 | globenewswire.com

Lantheus (NASDAQ:LNTH) Share Price Breaks Above Fifty Day Moving Average - Here's Why

October 30, 2026 | marketbeat.com

Lantheus (LNTH) Expected to Announce Earnings on Thursday

October 29, 2026 | marketbeat.com

ETFs Are Net Sellers of Lantheus (LNTH) on Oct. 22

October 26, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Now Rated "Hold" by Sell-Side Analysts

October 26, 2026 | marketbeat.com

Lantheus Holdings, Inc. $LNTH Stock Sold by Isthmus Partners LLC

October 23, 2026 | marketbeat.com

Lantheus receives FTC second request on Curium deal

October 22, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, CORT, AXSM, and LNTH Company Descriptions

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Axsome Therapeutics NASDAQ:AXSM

$141.69 -2.68 (-1.86%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$141.78 +0.09 (+0.07%)

As of 11/13/2026 07:58 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$72.94 -0.77 (-1.04%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$74.45 +1.51 (+2.07%)

As of 11/13/2026 07:57 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Lantheus NASDAQ:LNTH

$101.59 +0.34 (+0.34%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$101.60 +0.00 (+0.00%)

As of 11/13/2026 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATAI, CORT, AXSM, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATAI, CORT, AXSM, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATAI, CORT, AXSM, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, CORT, AXSM, and LNTH Company Descriptions

Atai Beckley NASDAQ:ATAI

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATAI, CORT, AXSM, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATAI, CORT, AXSM, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATAI, CORT, AXSM, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, CORT, AXSM, and LNTH Company Descriptions

Atai Beckley NASDAQ:ATAI

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools